High nasopharyngeal carriage of non-vaccine serotypes in Western Australian aboriginal people following 10 years of pneumococcal conjugate vaccination

PloS One
Deirdre A CollinsDeborah Lehmann

Abstract

Invasive pneumococcal disease (IPD) continues to occur at high rates among Australian Aboriginal people. The seven-valent pneumococcal conjugate vaccine (7vPCV) was given in a 2-4-6-month schedule from 2001, with a 23-valent pneumococcal polysaccharide vaccine (23vPPV) booster at 18 months, and replaced with 13vPCV in July 2011. Since carriage surveillance can supplement IPD surveillance, we have monitored pneumococcal carriage in western Australia (WA) since 2008 to assess the impact of the 10-year 7vPCV program. We collected 1,500 nasopharyngeal specimens from Aboriginal people living in varied regions of WA from August 2008 until June 2011. Specimens were cultured on selective media. Pneumococcal isolates were serotyped by the quellung reaction. Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis were carried by 71.9%, 63.2% and 63.3% respectively of children <5 years of age, and 34.6%, 22.4% and 27.2% of people ≥5 years. Of 43 pneumococcal serotypes identified, the most common were 19A, 16F and 6C in children <5 years, and 15B, 34 and 22F in older people. 7vPCV serotypes accounted for 14.5% of all serotypeable isolates, 13vPCV for 32.4% and 23vPPV for 49.9%, with little variation across all age groups...Continue Reading

References

Jun 14, 2003·New South Wales Public Health Bulletin
Nov 4, 2005·The Journal of Infectious Diseases·Rekha PaiUNKNOWN Active Bacterial Core Surveillance Team
Aug 31, 2006·The Pediatric Infectious Disease Journal·Kelly WatsonUNKNOWN Kalgoorlie Otitis Media Research Project Team
Nov 9, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ismar A Rivera-OliveroJacobus H de Waard
Jan 5, 2008·Paediatric and Perinatal Epidemiology·Deborah LehmannFiona J Stanley
Apr 4, 2008·Journal of Clinical Microbiology·Amanda Jane LeachPeter Stanley Morris
Nov 6, 2008·The Journal of Infectious Diseases·In H ParkUNKNOWN Active Bacterial Core Surveillance Team
Apr 28, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Deborah LehmannPeter Richmond
Apr 8, 2011·Emerging Infectious Diseases·Judith SpijkermanElisabeth A M Sanders
Apr 16, 2011·Lancet·Daniel M WeinbergerMarc Lipsitch
May 20, 2011·The Pediatric Infectious Disease Journal·Peter JacobyUNKNOWN Kalgoorlie Otitis Media Research Project Team
May 25, 2012·Vaccine·UNKNOWN WHO Publication
Jun 16, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A RocaR A Adegbola
Aug 24, 2012·Expert Review of Vaccines·Birgit SimellUNKNOWN Pneumococcal Carriage Group
Jan 2, 2013·Diagnostic Microbiology and Infectious Disease·Karen RudolphThomas Hennessy

❮ Previous
Next ❯

Citations

Apr 4, 2014·Upsala Journal of Medical Sciences·Birgitta Henriques-Normark, Staffan Normark
Dec 26, 2016·International Journal of Pediatric Otorhinolaryngology·Ruth B ThorntonPeter C Richmond
Aug 16, 2019·Communicable Diseases Intelligence·UNKNOWN National Centre for Immunisation Research and Surveillance (NCIRS)Peter McIntyre

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.